{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T02:32:34Z","timestamp":1790389954252,"version":"4.1.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,8,7]],"date-time":"2021-08-07T00:00:00Z","timestamp":1628294400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,8,7]],"date-time":"2021-08-07T00:00:00Z","timestamp":1628294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Deliv. and Transl. Res."],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s13346-021-01040-2","type":"journal-article","created":{"date-parts":[[2021,8,7]],"date-time":"2021-08-07T20:02:45Z","timestamp":1628366565000},"page":"2317-2327","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Rational combination of an immune checkpoint inhibitor with CSF1R inhibitor\u2013loaded nanoparticle enhances anticancer efficacy"],"prefix":"10.1007","volume":"11","author":[{"given":"Anujan","family":"Ramesh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaishali","family":"Malik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayat Anu","family":"Ranjani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harriet","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5713-2202","authenticated-orcid":false,"given":"Ashish A.","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,7]]},"reference":[{"key":"1040_CR1","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1101\/gad.314617.118","volume":"32","author":"H Gonzalez","year":"2018","unstructured":"Gonzalez H, Hagerling C, Werb Z. Roles of the immune system in cancer: from tumor initiation to metastatic progression. Genes Dev. 2018;32:1267\u201384. https:\/\/doi.org\/10.1101\/gad.314617.118.","journal-title":"Genes & development"},{"key":"1040_CR2","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3389\/fonc.2018.00049","volume":"8","author":"AR Poh","year":"2018","unstructured":"Poh AR, Ernst M. Targeting macrophages in cancer: from bench to bedside. Front Oncol. 2018;8:49. https:\/\/doi.org\/10.3389\/fonc.2018.00049.","journal-title":"Frontiers in oncology"},{"key":"1040_CR3","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1172\/JCI124615","volume":"129","author":"S Watanabe","year":"2019","unstructured":"Watanabe S, Alexander M, Misharin AV, Budinger GRS. The role of macrophages in the resolution of inflammation. J Clin Investig. 2019;129:2619\u201328. https:\/\/doi.org\/10.1172\/JCI124615.","journal-title":"The Journal of clinical investigation"},{"key":"1040_CR4","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.immuni.2014.06.013","volume":"41","author":"S Epelman","year":"2014","unstructured":"Epelman S, Lavine KJ, Randolph GJ. Origin and functions of tissue macrophages. Immunity. 2014;41:21\u201335. https:\/\/doi.org\/10.1016\/j.immuni.2014.06.013.","journal-title":"Immunity"},{"key":"1040_CR5","doi-asserted-by":"publisher","unstructured":"Roberts AW, et al. Tissue-resident macrophages are locally programmed for silent clearance of apoptotic cells. Immunity.\u00a02017;47:913\u2013927 e916. https:\/\/doi.org\/10.1016\/j.immuni.2017.10.006.","DOI":"10.1016\/j.immuni.2017.10.006"},{"key":"1040_CR6","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.immuni.2016.02.015","volume":"44","author":"TA Wynn","year":"2016","unstructured":"Wynn TA, Vannella KM. Macrophages in tissue repair, regeneration, and fibrosis. Immunity. 2016;44:450\u201362. https:\/\/doi.org\/10.1016\/j.immuni.2016.02.015.","journal-title":"Immunity"},{"key":"1040_CR7","doi-asserted-by":"publisher","first-page":"137","DOI":"10.3389\/fonc.2014.00137","volume":"4","author":"EK Colvin","year":"2014","unstructured":"Colvin EK. Tumor-associated macrophages contribute to tumor progression in ovarian cancer. Front Oncol. 2014;4:137. https:\/\/doi.org\/10.3389\/fonc.2014.00137.","journal-title":"Frontiers in oncology"},{"key":"1040_CR8","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1080\/17460441.2020.1733525","volume":"15","author":"S Kumar","year":"2020","unstructured":"Kumar S, Ramesh A, Kulkarni A. Targeting macrophages: a novel avenue for cancer drug discovery. Expert Opin Drug Discov. 2020;15:561\u201374. https:\/\/doi.org\/10.1080\/17460441.2020.1733525.","journal-title":"Expert Opin Drug Discov"},{"key":"1040_CR9","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s12929-019-0568-z","volume":"26","author":"Y Chen","year":"2019","unstructured":"Chen Y, et al. Tumor-associated macrophages: an accomplice in solid tumor progression. J Biomed Sci. 2019;26:78. https:\/\/doi.org\/10.1186\/s12929-019-0568-z.","journal-title":"J Biomed Sci"},{"key":"1040_CR10","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/816460","volume":"2015","author":"T Roszer","year":"2015","unstructured":"Roszer T. Understanding the mysterious M2 macrophage through activation markers and effector mechanisms. Mediators Inflamm. 2015;2015: 816460. https:\/\/doi.org\/10.1155\/2015\/816460.","journal-title":"Mediators Inflamm"},{"key":"1040_CR11","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.biomaterials.2016.09.034","volume":"112","author":"Y Wang","year":"2017","unstructured":"Wang Y, et al. Polymeric nanoparticles promote macrophage reversal from M2 to M1 phenotypes in the tumor microenvironment. Biomaterials. 2017;112:153\u201363. https:\/\/doi.org\/10.1016\/j.biomaterials.2016.09.034.","journal-title":"Biomaterials"},{"key":"1040_CR12","doi-asserted-by":"publisher","unstructured":"Martinez FO, Gordon S. The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000Prime Rep. 2014;6:13.\u00a0https:\/\/doi.org\/10.12703\/P6-13.","DOI":"10.12703\/P6-13"},{"key":"1040_CR13","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.cmet.2019.06.001","volume":"30","author":"I Vitale","year":"2019","unstructured":"Vitale I, Manic G, Coussens LM, Kroemer G, Galluzzi L. Macrophages and metabolism in the tumor microenvironment. Cell Metab. 2019;30:36\u201350. https:\/\/doi.org\/10.1016\/j.cmet.2019.06.001.","journal-title":"Cell Metab"},{"key":"1040_CR14","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/948098","volume":"2012","author":"NB Hao","year":"2012","unstructured":"Hao NB, et al. Macrophages in tumor microenvironments and the progression of tumors. Clin Dev Immunol. 2012;2012: 948098. https:\/\/doi.org\/10.1155\/2012\/948098.","journal-title":"Clin Dev Immunol"},{"key":"1040_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.590941","volume":"10","author":"Z Ge","year":"2020","unstructured":"Ge Z, Ding S. The crosstalk between tumor-associated macrophages (TAMs) and tumor cells and the corresponding targeted therapy. Front Oncol. 2020;10: 590941. https:\/\/doi.org\/10.3389\/fonc.2020.590941.","journal-title":"Frontiers in oncology"},{"key":"1040_CR16","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1097\/CCO.0b013e328354c16b","volume":"24","author":"HT Temple","year":"2012","unstructured":"Temple HT. Pigmented villonodular synovitis therapy with MSCF-1 inhibitors. Curr Opin Oncol. 2012;24:404\u20138. https:\/\/doi.org\/10.1097\/CCO.0b013e328354c16b.","journal-title":"Current opinion in oncology"},{"key":"1040_CR17","doi-asserted-by":"publisher","first-page":"38","DOI":"10.3389\/fcell.2018.00038","volume":"6","author":"L Cassetta","year":"2018","unstructured":"Cassetta L, Kitamura T. Targeting tumor-associated macrophages as a potential strategy to enhance the response to immune checkpoint inhibitors. Front Cell Dev Biol. 2018;6:38. https:\/\/doi.org\/10.3389\/fcell.2018.00038.","journal-title":"Front Cell Dev Biol"},{"key":"1040_CR18","doi-asserted-by":"publisher","first-page":"24576","DOI":"10.18632\/oncotarget.25191","volume":"9","author":"VD Edwards","year":"2018","unstructured":"Edwards VD, et al. Targeting of colony-stimulating factor 1 receptor (CSF1R) in the CLL microenvironment yields antineoplastic activity in primary patient samples. Oncotarget. 2018;9:24576\u201389. https:\/\/doi.org\/10.18632\/oncotarget.25191.","journal-title":"Oncotarget"},{"key":"1040_CR19","doi-asserted-by":"publisher","unstructured":"Quail DF, et al. The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas. Science.\u00a02016;352:aad3018.\u00a0https:\/\/doi.org\/10.1126\/science.aad3018.","DOI":"10.1126\/science.aad3018"},{"key":"1040_CR20","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1056\/NEJMoa1411366","volume":"373","author":"WD Tap","year":"2015","unstructured":"Tap WD, et al. Structure-guided blockade of CSF1R kinase in tenosynovial giant-cell tumor. New Engl J Med. 2015;373:428\u201337. https:\/\/doi.org\/10.1056\/NEJMoa1411366.","journal-title":"The New England journal of medicine"},{"key":"1040_CR21","doi-asserted-by":"publisher","unstructured":"Morrissey MA, Kern N, Vale RD. CD47 Ligation repositions the inhibitory receptor SIRPA to suppress integrin activation and phagocytosis. Immunity. 2020;53:290\u2013302 e296. https:\/\/doi.org\/10.1016\/j.immuni.2020.07.008.","DOI":"10.1016\/j.immuni.2020.07.008"},{"key":"1040_CR22","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41551-018-0254-6","volume":"2","author":"A Kulkarni","year":"2018","unstructured":"Kulkarni A, et al. A designer self-assembled supramolecule amplifies macrophage immune responses against aggressive cancer. Nat Biomed Eng. 2018;2:589\u201399. https:\/\/doi.org\/10.1038\/s41551-018-0254-6.","journal-title":"Nature Biomedical Engineering"},{"key":"1040_CR23","doi-asserted-by":"publisher","first-page":"1904364","DOI":"10.1002\/adma.201904364","volume":"31","author":"A Ramesh","year":"2019","unstructured":"Ramesh A, Kumar S, Nandi D, Kulkarni A. CSF1R- and SHP2-inhibitor-loaded nanoparticles enhance cytotoxic activity and phagocytosis in tumor-associated macrophages. Adv Mater. 2019;31:1904364. https:\/\/doi.org\/10.1002\/adma.201904364.","journal-title":"Advanced Materials"},{"key":"1040_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2019.119559","volume":"227","author":"A Ramesh","year":"2020","unstructured":"Ramesh A, Brouillard A, Kumar S, Nandi D, Kulkarni A. Dual inhibition of CSF1R and MAPK pathways using supramolecular nanoparticles enhances macrophage immunotherapy. Biomaterials. 2020;227: 119559. https:\/\/doi.org\/10.1016\/j.biomaterials.2019.119559.","journal-title":"Biomaterials"},{"key":"1040_CR25","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1038\/s41551-018-0236-8","volume":"2","author":"CB Rodell","year":"2018","unstructured":"Rodell CB, et al. TLR7\/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy. Nat Biomed Eng. 2018;2:578\u201388. https:\/\/doi.org\/10.1038\/s41551-018-0236-8.","journal-title":"Nat Biomed Eng"},{"key":"1040_CR26","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s13045-019-0779-5","volume":"12","author":"A Akinleye","year":"2019","unstructured":"Akinleye A, Rasool Z. Immune checkpoint inhibitors of PD-L1 as cancer therapeutics. J Hematol Oncol. 2019;12:92. https:\/\/doi.org\/10.1186\/s13045-019-0779-5.","journal-title":"J Hematol Oncol"},{"key":"1040_CR27","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1158\/0008-5472.Can-18-3208","volume":"79","author":"H Xiong","year":"2019","unstructured":"Xiong H, et al. Anti\u2013PD-L1 treatment results in functional remodeling of the macrophage compartment. Cancer Res. 2019;79:1493\u2013506. https:\/\/doi.org\/10.1158\/0008-5472.Can-18-3208.","journal-title":"Cancer research"},{"key":"1040_CR28","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1136\/gutjnl-2019-318419","volume":"68","author":"Y Zhu","year":"2019","unstructured":"Zhu Y, et al. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade. Gut. 2019;68:1653\u201366. https:\/\/doi.org\/10.1136\/gutjnl-2019-318419.","journal-title":"Gut"},{"key":"1040_CR29","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1016\/j.cell.2018.11.003","volume":"175","author":"MM Gubin","year":"2018","unstructured":"Gubin MM, et al. High-Dimensional analysis delineates myeloid and lymphoid compartment remodeling during successful immune-checkpoint cancer therapy. Cell. 2018;175:1443. https:\/\/doi.org\/10.1016\/j.cell.2018.11.003.","journal-title":"Cell"},{"key":"1040_CR30","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.chroma.2012.03.056","volume":"1238","author":"S Zhang","year":"2012","unstructured":"Zhang S, et al. Biocompatible phosphatidylcholine bilayer coated on magnetic nanoparticles and their application in the extraction of several polycyclic aromatic hydrocarbons from environmental water and milk samples. J Chromatogr A. 2012;1238:38\u201345. https:\/\/doi.org\/10.1016\/j.chroma.2012.03.056.","journal-title":"J Chromatogr A"},{"key":"1040_CR31","doi-asserted-by":"publisher","first-page":"166","DOI":"10.3389\/fbioe.2020.00166","volume":"8","author":"R Rampado","year":"2020","unstructured":"Rampado R, Crotti S, Caliceti P, Pucciarelli S, Agostini M. Recent advances in understanding the protein corona of nanoparticles and in the formulation of \u201cstealthy\u201d nanomaterials. Front Bioeng Biotechnol. 2020;8:166. https:\/\/doi.org\/10.3389\/fbioe.2020.00166.","journal-title":"Front Bioeng Biotechnol"},{"key":"1040_CR32","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.3324\/haematol.2018.197194","volume":"103","author":"M Pollari","year":"2018","unstructured":"Pollari M, et al. PD-L1(+) tumor-associated macrophages and PD-1(+) tumor-infiltrating lymphocytes predict survival in primary testicular lymphoma. Haematologica. 2018;103:1908\u201314. https:\/\/doi.org\/10.3324\/haematol.2018.197194.","journal-title":"Haematologica"},{"key":"1040_CR33","doi-asserted-by":"publisher","first-page":"1919082","DOI":"10.1155\/2019\/1919082","volume":"2019","author":"D Lu","year":"2019","unstructured":"Lu D, et al. Beyond T Cells: Understanding the role of PD-1\/PD-L1 in tumor-associated macrophages. J Immunol Res. 2019;2019:1919082. https:\/\/doi.org\/10.1155\/2019\/1919082.","journal-title":"Journal of immunology research"},{"key":"1040_CR34","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.lungcan.2019.08.023","volume":"136","author":"R Sumitomo","year":"2019","unstructured":"Sumitomo R, et al. PD-L1 expression on tumor-infiltrating immune cells is highly associated with M2 TAM and aggressive malignant potential in patients with resected non-small cell lung cancer. Lung Cancer. 2019;136:136\u201344. https:\/\/doi.org\/10.1016\/j.lungcan.2019.08.023.","journal-title":"Lung Cancer"},{"key":"1040_CR35","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/nri2735","volume":"10","author":"WE Paul","year":"2010","unstructured":"Paul WE, Zhu J. How are T(H)2-type immune responses initiated and amplified? Nat Rev Immunol. 2010;10:225\u201335. https:\/\/doi.org\/10.1038\/nri2735.","journal-title":"Nature reviews. Immunology"},{"key":"1040_CR36","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1023\/a:1005904704618","volume":"17","author":"JE Albina","year":"1998","unstructured":"Albina JE, Reichner JS. Role of nitric oxide in mediation of macrophage cytotoxicity and apoptosis. Cancer Metastasis Rev. 1998;17:39\u201353. https:\/\/doi.org\/10.1023\/a:1005904704618.","journal-title":"Cancer Metastasis Rev"},{"key":"1040_CR37","doi-asserted-by":"publisher","first-page":"4821","DOI":"10.21037\/jtd.2017.10.152","volume":"9","author":"HY Tu","year":"2017","unstructured":"Tu HY, Zhang Q, Wu YL. Optimal pembrolizumab dosing for non-small cell lung cancer: further studies still needed. J Thorac Dis. 2017;9:4821\u20134. https:\/\/doi.org\/10.21037\/jtd.2017.10.152.","journal-title":"J Thorac Dis"},{"key":"1040_CR38","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/s00415-017-8695-5","volume":"265","author":"JT Miyauchi","year":"2018","unstructured":"Miyauchi JT, Tsirka SE. Advances in immunotherapeutic research for glioma therapy. J Neurol. 2018;265:741\u201356. https:\/\/doi.org\/10.1007\/s00415-017-8695-5.","journal-title":"J Neurol"},{"key":"1040_CR39","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1158\/1078-0432.CCR-19-1040","volume":"26","author":"Y Liu","year":"2020","unstructured":"Liu Y, et al. Immune Cell PD-L1 Colocalizes with macrophages and is associated with outcome in pd-1 pathway blockade therapy. Clin Cancer Res Official J Am Assoc Cancer Res. 2020;26:970\u20137. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-1040.","journal-title":"Clinical cancer research : an official journal of the American Association for Cancer Research"}],"container-title":["Drug Delivery and Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-021-01040-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13346-021-01040-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-021-01040-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,4]],"date-time":"2021-11-04T13:23:24Z","timestamp":1636032204000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13346-021-01040-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,7]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1040"],"URL":"https:\/\/doi.org\/10.1007\/s13346-021-01040-2","relation":{},"ISSN":["2190-393X","2190-3948"],"issn-type":[{"value":"2190-393X","type":"print"},{"value":"2190-3948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,7]]},"assertion":[{"value":"26 July 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the authors read and approved the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All institutional and national guidelines for the care and use of laboratory animals were followed and approved by the appropriate institutional committees.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Animal studies"}},{"value":"A. R. and A. K. are inventors on a pending patent application filed by the University of Massachusetts Amherst (filed October 23, 2020. Appl. No. 17\/077,041). The authors declare no other competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}